 GAITHERSBURG, Md., Sept. 28, 2021 GLOBE NEWSWIRE -- Altimmune, Inc. Nasdaq: ALT, a clinical-stage biopharmaceutical company, today announced positive results from a 12-week, Phase 1 trial of pemvidutide proposed INN, formerly known as ALT-801, an investigational glucagon-like peptide-1 GLP-1glucagon dual receptor agonist. 